Literature DB >> 950096

Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome.

A P Geubel, R H Keller, W H Summerskill, E R Dickson, T B Tomasi, R G Shorter.   

Abstract

A method is described for determining the cytotoxicity of normal and autologous lymphocytes for 51Cr-labeled isolated parenchymal liver cells in a low aggressor to target cell ratio. Results were compared from patients with chronic active liver disease (CALD), chronic persistent hepatitis (CPH), miscellaneous liver diseases, or primary biliary cirrhosis (PBC). In 53% of CALD patients, lymphocytes showed greater cytotoxicity for hepatic cells than did normal allogenic lymphocytes, but in 32% there was significantly less 51Cr release than normal; in the remainder, results were in the normal range. Lymphocyte cytotoxicity was greater in patients with disease of short duration and less in those treated with corticosteroids. In untreated CALD, decreased 51Cr release was associated with the presence of plasma factor(s) inhibiting phytohemagglutinin (PHA)-induced transformation of normal lymphocytes. Lymphocytes from approximately 50% of the patients with PBC exhibited cytotoxicity for hepatic cells but 25% showed less 51Cr release than controls and the remaining patients had results in the normal range. Lymphocyte cytotoxicity was also greater during the earlier stage of PBC. In contrast to CALD, decreased 51Cr release was not associated with the presence of plasma factor(s) inhibiting PHA-induced transformation of normal lymphocytes. Our findings support the hypothesis of in vivo lymphocyte-mediated liver cell damage in CALD and PBC, suggesting a potentially important role for lymphocyte suppression in the pathogenesis of both diseases.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950096

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

1.  Chronic hepatitis: a retrospective study in 34 dogs.

Authors:  C Fuentealba; S Guest; S Haywood; B Horney
Journal:  Can Vet J       Date:  1997-06       Impact factor: 1.008

2.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls.

Authors:  L Si; T L Whiteside; R R Schade; T E Starzl; D H Van Thiel
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

4.  Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years.

Authors:  R C Gupta; E R Dickson; F C McDuffie; A H Baggenstoss
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

5.  Disordered immunoregulatory functions in patients with chronic active hepatitis.

Authors:  A Nonomura; M Tanino; H Kurumaya; G Ohta; Y Kato; K Kobayashi
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Occurrence and significance of IgG liver membrane autoantibodies (LMA) in chronic liver diseases of different aetiology.

Authors:  R Meliconi; M V Stancari; M Garagnani; M Baraldini; G F Stefanini; F Miglio; G Gasbarrini
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

7.  Lymphocyte-mediated cytotoxicity in isoniazid-associated hepatitis.

Authors:  R J Warrington; S L Olivier
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

8.  Mechanisms responsible for antibody-dependent, cell-mediated cytotoxicity to isolated hepatocytes in chronic active hepatitis.

Authors:  C Gonzales; A M Cochrane; A L Eddleston; R Williams
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

9.  Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release.

Authors:  E Fernandez-Cruz; P Escartin; A Bootello; M Kreisler; J M Segovia de Arana
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

10.  Lymphocyte cytotoxicity in chronic active hepatitis: effect of therapy and correlations with clinical and histological changes.

Authors:  A M Cochrane; A Moussouros; A Smith; B Portmann; A L Eddleston; R Williams
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.